# Targeting Endometrial Cancer with Novel Small Molecule Modulators of PP2A

> **NIH NIH P20** · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2024 · $307,000

## Abstract

Project Summary: Overall
The goal of the Nebraska Center for Molecular Target Discovery and Development (CMTDD) is to establish and
expand physical and intellectual resources at the University of Nebraska Medical Center (UNMC) and the
University of Nebraska system to catalyze the identification, validation, and development of approaches for
manipulation of molecular targets implicated in clinically important diseases. We perceive an increasing
expectation by journals and granting agencies for progressively sophisticated model systems and data sets.
Acquisition of these systems and generation of high-content data often requires a substantial investment in time
and money that taxes limited research resources. To enhance the competitiveness of CMTDD Research Project
Leaders (RPLs) and other university faculty members during Phase 2, the CMTDD recently invested in the
development of technologies to enhance the sophistication of investigator research while minimizing the cost of
access. These technologies: single-cell and spatial transcriptomic analysis, organoid generation and
manipulation, and inhibitor and proteolysis-targeting chimera (PROTAC) synthesis will be integrated into three
Phase 2 CMTDD cores. These investments will enhance the research capabilities of the institution, expand the
translational capacity of its faculty, facilitate the training, mentoring, and career advancement of promising new
faculty, and efficiently drive discovery and development for the improvement of human health in Nebraska and
the nation. Phase 2 RPLs bring a breadth of cutting-edge expertise to the CMTDD. With mentoring and ready
access to CMTDD-supported cores, our RPLs will become self-supporting faculty members invaluable to the
future success of UNMC. Our Phase 2 RPLs share both a passion for exploration of the basic biologic principles
that underly cell homeostasis and a belief that many diseases can be effectively classified and characterized
through detailed genomic, genetic, and molecular analyses that identify drivers and vulnerabilities from which
will emerge unique therapeutic approaches. To realize this vision, the CMTDD will: 1) maintain an Administrative
Core and mentoring program that successfully graduated all but one of its initial RPLs in the first four years of
support; 2) increase research capacity through newly established state-of-the-art scientific cores for single-cell
and spatial transcriptomics, organoid development, and inhibitor and PROTAC synthesis and validation; and 3)
provide low- or no-cost access to these technologies and reagents as an affordable means for increasing the
impact of investigator research.

## Key facts

- **NIH application ID:** 10953932
- **Project number:** 3P20GM121316-07S1
- **Recipient organization:** UNIVERSITY OF NEBRASKA MEDICAL CENTER
- **Principal Investigator:** Robert E. Lewis
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $307,000
- **Award type:** 3
- **Project period:** 2018-03-16 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10953932

## Citation

> US National Institutes of Health, RePORTER application 10953932, Targeting Endometrial Cancer with Novel Small Molecule Modulators of PP2A (3P20GM121316-07S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10953932. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*